What is Daprodustat and how does it work?
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being developed for the treatment of anemia in patients with chronic kidney disease (CKD), including those with end-stage renal disease (ESRD) [1].
Mechanism of Action
Daprodustat was designed to activate the body's natural response to low oxygen levels, or hypoxia, by stabilizing hypoxia-inducible factor-alpha (HIF-α), a protein that regulates oxygen homeostasis and gene expression. This is thought to promote the production of erythropoietin (EPO), a hormone primarily produced in the kidneys that stimulates the production of red blood cells in the bone marrow [2].
Clinical Trials
Clinical trials have demonstrated the efficacy and safety of daprodustat in treating anemia in patients with CKD and ESRD. In a Phase 3 trial, daprodustat was shown to increase hemoglobin levels and reduce the need for erythropoiesis-stimulating agents (ESAs) in patients with non-dialysis-dependent CKD [3]. Another Phase 3 trial demonstrated the efficacy of daprodustat in increasing hemoglobin levels and improving quality of life in patients with ESRD on dialysis [4].
Side Effects and Safety
The most common side effects of daprodustat include nausea, diarrhea, headache, fatigue, and dizziness. In clinical trials, daprodustat was generally well-tolerated, with a safety profile similar to that of ESAs. However, as with any medication, there is a risk of serious side effects, including anaphylaxis, hypersensitivity reactions, and tumor growth promotion [5].
Patent Expiration
The daprodustat patent is held by GlaxoSmithKline, and is currently listed on DrugPatentWatch.com as expiring in 2027 [6].
Alternatives and Competition
Other treatments for anemia in patients with CKD and ESRD include ESAs, such as epoetin alfa and darbepoetin alfa, and iron supplements. Biosimilars, including epoetin alfa and darbepoetin alfa, have been approved for use in the US and EU, but the availability of these alternatives may depend on the patent status of the specific product [7].
References
[1] GlaxoSmithKline. (2022). Daprodustat. ClinicalTrials.gov.
[2] National Institutes of Health. (2022). Erythropoetin. MedlinePlus.
[3] GlaxoSmithKline. (2021). Phase 3 trial results of daprodustat in non-dialysis-dependent CKD.
[4] GlaxoSmithKline. (2021). Phase 3 trial results of daprodustat in ESRD on dialysis.
[5] FDA. (2022). Daprodustat.
[6] DrugPatentWatch.com. (2023). Daprodustat patent.
[7] Biosimilars: A Guide for Healthcare Professionals. (2022). American Society of Hematology.
[8] EPO, Anemia, and CKD: Current Perspectives. (2022). American Journal of Kidney Diseases.
Sources:
1. https://ClinicalTrials.gov
2. https://MedlinePlus.gov
3. https://DrugPatentWatch.com